Surgical Management of Keratoconus Jim Owen, OD MBA, FAAO



Financial Disclosure

 Jim Owen, OD has no financial interests in any of the products or companies discussed in this program

Keratoconus



Asymmetric, bilateral progressive, thinning disorder of the cornea

Keratoconus

- Adolescent onset
- Progresses over 10-20 years
- Prevalence: 50-230/100,000¹
- Incidence
 - 1/5000 in general population²
 2% in patients seeking surgical correction of refractive average
- errors
- About 10% of patients with KC require corneal transplantation

How Many PKP's Occur in the United States Secondary to Keratoconus?

- 1.500
- 2.2500
- 3.5000
- 4.7500

Penetrating Keratoplasty



Who is not at Risk

Percentage of Smokers and Nonsmokers in Average German Population and Patients With Keratoconus						
	Average Population	Keratoconus				
Smokers	30	5				
Non-Smokers	70	95				





Collagen Cross-Linking History

Studied since 1994

- University of Dresden
 Theo Seiler

 - Eberhard Spoerl

Gregory Wollensak

has been in some ball of the

Induction of Gross-links in Corneal Tissue HERITAGE CONTRACTOR AND ADDRESS OF THE ADDRESS OF T stage information of Disasters Description in which

III International Congress of Corneal Cross-linking

- Abbreviations in literature confusing
 - CCC
 - C3R
 - CCL

Universal standard going forward - CXL



UVA Corneal Absorption in Presence of Riboflavin					
		Irradiance			
	0	3.00 mW/cm ²	Damage Threshold		
~	100	1.49 mW/cm ²			
suo.	200	0.74 mW/cm ²			
micr	300	0.36 mW/cm ²	 Keratocytes: 0.5 mW/cm² Endothelium: 0.3 mW/cm² 		
4	400	0.18 mW/cm ²			
De	500	0.09 mW/cm ²			
	600	0.06 mW/cm ²			

Effects of Corneal Cross-Linking



















Which step in this treatment gives you the most anxiety?

- 1. Removing epithelium
- 2. Applying Riboflavin
- 3. Exposing eye to UV Light
- 4. Applying Bandage Contact Lens
- 5. Watching Epithelium Grow

Epithelial-On Crosslinking (Transepithelial CXL)

- First performed by Brian Boxer Wachler in 2004.
 A few peer reviewed articles in medical literature
- Questions/concerns raised by Seiler and others:
 - Can enough riboflavin penetrate into the cornea?
 Danger to endothelium & macula if too much UV enters the eye
 - Research: After 30 minutes:
 - Insufficient riboflavin concentration in the corneal stroma with Epi-On?
 - Does the Epithelium absorb too much UV:

Advantages of Epi-ON CXL

- Faster visual recovery:
 - Return to contact lenses in days
- Less pain
- Avoids risk of delays in epithelial healing
- Reduced risk of infection
- Reduced development of corneal haze

<section-header><section-header><section-header>

Keys to Trans-epithelial CXL

- Riboflavin 1% with gum cellulose Q2 min;
 From local compounding pharmacies
- Topical Tetracaine with BAK provided Q2 to 5 min
- Corneal Protector sponge used
- 60-80 minutes of Riboflavin drops required







Keys to Trans-epithelial CXL

- stroma
- Minimum of 400 micron pach required before UV light



uorescence of cornea with UV liab



Questions

Is it safe? Does it work? Who is a candidate? What is my role?



Evaluation of Studies BCVA

- Siena Eye Crosslinking Study
- Transepithelial Crosslinking Study

 - 1 patient 1 line decrease BCVA
 - 0 patients 2 line decrease BCVA

Safety of corneal collagen crosslinking with UV-A and riboflavin in progressive keratoconus.

- No change in endothelial cell thickness at 6 months and 12 months
- No change in foveal thickness at 6 months and 12 months

Cornea, 2010 Apr;29(4):409-11. Safety of corneal collagen cross-linking with UV-A and riboflavin in progressive keratoconus.

Permanent Stromal Haze after Crosslinking

- 163 Eyes of 127 patients treated with Riboflavin and UV light (370nm)
- At 1 year 8.6% developed permanent stromal haze
- Study compared the clear group to haze group

Raiskup F. Permanent stromal haze after Riboflavin UV Crosslinking in Keratoconus JRS; Sept 2009.





Cross-Linking And Keratoconus						
	Mean + SD	Posite				
No. of patients	22					
Mean follow-up	$23.2\pm12.9\ \text{mos}$					
Preoperative K progression	1.42 ± 1.18 D					
Postoperative K regression	2.01 ± 1.74	0.0001				
Postoperative regression in SE	1.14 ± 2.18 D	0.030				
Postoperative increase in VA	1.26 ± 1.5 lines	0.026				
Wollensak, Spoerl, and Seiler, AJO 135:620, 2003.						







Topographic Symmetry



Prospective Randomized Trial Design: Australia

- Christine Wittig, Grant Snibson, Mark Whiting, Laurie Sullivan, Richard Lindsay, Hugh Taylor
- Melbourne, Brisbane
- Inclusion criteria

 - Keratoconus
 Documented progression over 12 mo.
 - CT > 400µ • Age 16-50
 - No corneal surgery or other pathology
- Cross-over at 6 months if progression in control eyes

Prospective Randomized Trial Interim Results

- 4/2006 11/2006
- 66 eyes randomized
- Mean age 27.6 y

Prospective Randomized Trial Treatment Parameters

- Removal of epithelium
- Riboflavin drops q3 min x 15 min
- UVA with riboflavin g3 min
- Postoperative
 - TBL
 - Choramphenicol until ED healed
 - FML x 2 wk









- 44 Eyes with progressive keratoconus
- Mean K less than 55
- Greater than 400 microns thickness
- Cornea clear without scars







K Change as Compared to Fellow Eye



Comparison of Sequential vs Sameday Simultaneous Collagen Crosslinking and Topography-guided PRK for Treatment of Keratoconus

Anastasios John Kanellopoulos, MD

Patient data and treatment

- 325 Keratoconus eyes
- Topography guided custom PRK
- CXL with riboflavin and UV light
- Maximum treatment 50 microns
- Treated 70% of cyl

Results

- BCVA improved 0.39 logmar to 0.11
- 3.2 Diopter reduction in SE
- 3.5D Flatten of mean K's

Pentacam Changes



What is the best parameter to measure success of CXL

- 1. Best Corrected Vision
- **2.** Topographic Changes (I/S Ratio)
- **3.** Change in Higher Order Aberrations
- 4. Patient Satisfaction Survey
- 5. Percentage of Soft Toric Wearers

Conclusions : CXL

Halts progression of ectatic corneal diseases

- Decreases corneal curvature and thickness
- Regularizes corneal surface
- Improves UCVA and BSCVA
- Effect lasts indefinitely
- Offers safe and effective treatment for conditions with no currently available treatment and may avoid
 - 15% of corneal transplants
 - Disability, cost, loss of productivity, CTL

Indications for Intacs in Keratoconus or Post-Lasik Ectasia

- Patients are contact lens intolerant
- Are considering a cornea transplant
- Clear central cornea with no scar
- CL Visual acuity limits lifestyle
- Corneal thickness adequate at the site of proposed placement of segments

Contra-indications for Intacs

- Cornea with central scars and opacities
- Cornea too thin at the site of the Intacs implantation
- Patients with unrealistic expectations



Intacs with Sequential CXL

- Effects of both treatments are synergistic
 - Increased K flattening
 - Increased BCVA
 - Increased UCVA

 - Kamburoglu G, Ertan A: Intacs Implantation with Sequential CXL Treatment in Postoperative LASIK Ectasia. J Refractive Surg. 2008;24:7:S726-S729
 Chan CC, Sharma M, Wachler BS: Effect of inferior-segment Intac with and without C3-R on keratoconus. J Cataract Refract Surg. 2007;33:75-80.



















All









- 38 y/o male
- OD 3.00-1.25x135 20/25
- Soft toric never aligns to stable location
- Patient does not like comfort of RGP
- Vision with RGP 20/20-



What is your recommended treatment?

- 1.SynergEyes
- 2.CXL
- 3.Intacs
- 4.CXL and Intacs
- 5.PRK



Keratoconus Progression

- Early Keratoconus Moves from Soft toric to RGP Lenses
- Advancing Keratoconus RGP lenses to specialty RGP / Hybrid Lenses
 - Consider CXL / Intacs
- Advanced Keratoconus Decreased wearing time
 - Intacs if stable
 - Intacs and CXL if not stable

